Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 18/20 | 0.51 |
| ▸ | PGGT1B | P53609 | 17/20 | 0.51 |
| ▸ | FNTB | P49356 | 17/20 | 0.51 |
| ▸ | DNAJA1 | P31689 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7181655 | 1.00 | FNTA (0.51) | FNTAPGGT1BFNTBDNAJA1KCNH2 | |
| SCHEMBL7184432 | 1.00 | FNTA (0.51) | FNTAPGGT1BFNTBDNAJA1KCNH2 | |
| SCHEMBL7177802 | 1.00 | FNTA (0.51) | FNTAPGGT1BFNTBDNAJA1KCNH2 | |
| SCHEMBL7185080 | 1.00 | FNTA (0.51) | FNTAPGGT1BFNTBDNAJA1KCNH2 | |
| Hydrochloric Acid SCHEMBL7186139 | 0.99 | FNTA (0.51) | FNTAPGGT1BFNTBDNAJA1KCNH2 | |
| Hydrochloric Acid SCHEMBL7184754 | 0.99 | FNTA (0.51) | FNTAPGGT1BFNTBDNAJA1KCNH2 | |
| Hydrochloric Acid SCHEMBL7180259 | 0.99 | FNTA (0.51) | FNTAPGGT1BFNTBDNAJA1KCNH2 | |
| SCHEMBL7253295 | 0.77 | FNTA (0.51) | FNTAPGGT1BFNTBDNAJA1KCNH2 | |
| Hydrochloric Acid SCHEMBL7252683 | 0.77 | FNTA (0.51) | FNTAPGGT1BFNTBDNAJA1KCNH2 | |
| SCHEMBL3499358 | 0.74 | FNTA (0.74) | FNTAPGGT1BFNTBDNAJA1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6632818-B2 | Piperazine-containing macrocyclic compounds | MERCK & CO., INC. | 2003-10-14 | — | — | US | claimed |
| US-20030134860-A1 | Inhibitors of prenyl-protein transferase | MERCK SHARP & DOHME CORP. | 2003-07-17 | — | — | US | claimed |
| US-6632818-B2 | Piperazine-containing macrocyclic compounds | MERCK & CO., INC. | 2003-10-14 | — | — | US | disclosed |
| US-20030134860-A1 | Inhibitors of prenyl-protein transferase | MERCK SHARP & DOHME CORP. | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134860-A1 | Inhibitors of prenyl-protein transferase | FNTA, FNTB, RCE1 | FNTA 1/4885PGGT1B 108/4885FNTB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.